Efficacy of conventional and extended intra-mammary treatment of persistent sub-clinical mastitis with cefquinome in lactating dairy cows

Abstract

The objectives of the present study were to evaluate the efficacy of intra-mammary-administered cefquinome for the treatment of sub-clinical mastitis in lactating dairy cows and to determine if extended therapy would enhance treatment efficacy. Seventy-three Holstein dairy cows from a single farm with 150 infected quarters were enrolled in the study. Infected cows were allocated randomly to one of three treatment regimens: (1) conventional (standard) regimen: 75 mg of cefquinome administered three times at 16-h intervals (25 infected cows, 52 intra-mammary infections (IMI)), (2) extended regimen: 75 mg of cefquinome administered six times at 16-h intervals (26 infected cows, 58 IMI) and (3) negative untreated control group (22 cows, 40 IMI). Most IMI were caused by coagulase-negative staphylococci, streptococci other than Streptococcus agalactiae and coliforms. The overall bacteriological cure (BC) rates for sub-clinical IMI were 84.61%, 91.37% and 20% for the conventional, extended and the control groups, respectively, indicating a higher BC rate for the treated groups than the control group (P < 0.001). Significant differences in somatic cell count (SCC) were detected between the treated versus the control group (P < 0.001). No differences, concerning the BC rate or SCC, were observed between the extended and the conventional groups. Although fat and protein percentages increased in the treated groups, there were no significant differences in post-treatment milk production between the groups. Results of this study indicate that cefquinome therapy was effective in reducing SCC and eliminating sub-clinical IMI in lactating dairy cows, but extended therapy did not enhance treatment efficacy.

Pharmacokinetics and pharmacodynamics of intramammary cefquinome in lactating goats with and without experimentally induced Staphylococcus aureus mastitis

“…It is important to note that because we did not have an untreated control group in the study reported here we cannot claim that IMM cefquinome was an efficacious treatment for experimentally induced S. aureus mastitis in goats. Efficacy is supported by the results of studies in dairy cows, demonstrating that IMM cefquinome is efficacious when infused in cows with coliform mastitis (Shpigel et al, 1997), Streptococcus uberis mastitis (Milne et al, 2005), caused by coagulase-negative staphylococci, environmental streptococci, and coliforms (Kasravi et al, 2011), S. aureus mastitis (Swinkels, Cox, Schukken, & Lam, 2013), and a number of mastitis pathogens (Bradley & Green, 2009).…”

“…aureus mastitis in goats. Efficacy is supported by the results of studies in dairy cows, demonstrating that IMM cefquinome is efficacious when infused in cows with coliform mastitis (Shpigel et al, ), Streptococcus uberis mastitis (Milne et al, ), caused by coagulase‐negative staphylococci, environmental streptococci, and coliforms (Kasravi et al, ), S . aureus mastitis (Swinkels, Cox, Schukken, & Lam, ), and a number of mastitis pathogens (Bradley & Green, ).…”

Selective degradation of tetracycline antibiotics present in raw milk by electrochemical method

“…Mastitis is one of the representative diseases in dairy cows and remains the most costly disease. It reduces milk yield and affects the quality of the milk in all dairy-producing countries in the world [1]. It is estimated that between 2 and 55% of all lactating cows will include a mastitis infection [2].…”

Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves

“…(Perry & Schentag, 2001). Cefquinome (CFQ), a fourth-generation cephalosporin, is effective against clinically important bacteria such as Streptococcus spp., Staphylococcus spp., Enterobacteriaceae, Pasteurellaceae, and gram-positive anaerobes (Amiridis, Fthenakis, Dafopoulos, Papanikolaou, & Mavrogianni, 2003;Kasravi et al, 2011;Limbert et al, 1991;Orden, Ruiz-Santa-Quiteria, García, Cid, & De La Fuente, 1999). CFQ has been recommended for the treatment of septicemia caused by E. coli in neonatal calves at 2 mg/kg dose, given once daily (CVMP, 1995;Thomas et al, 2004).…”